Free Trial

BioLineRx (BLRX) Stock Price, News & Analysis

0.00 (0.00%)
(As of 05/22/2024 ET)
Today's Range
50-Day Range
52-Week Range
176,270 shs
Average Volume
373,995 shs
Market Capitalization
$49.56 million
P/E Ratio
Dividend Yield
Price Target

BioLineRx MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
3,287.1% Upside
$21.00 Price Target
Short Interest
0.51% of Shares Sold Short
Dividend Strength
News Sentiment
0.00mentions of BioLineRx in the last 14 days
Based on 3 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($1.03) to ($0.93) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.84 out of 5 stars

Medical Sector

622nd out of 921 stocks

Pharmaceutical Preparations Industry

266th out of 394 stocks

BLRX stock logo

About BioLineRx Stock (NASDAQ:BLRX)

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

BLRX Stock Price History

BLRX Stock News Headlines

BLRX: First Aphexda Sales Recognized
BLRX Mar 2024 1.000 call
BLRX: Poster Presentations
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
BLRX May 2024 1.000 put
See More Headlines
Receive BLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$4.80 million
Book Value
$0.18 per share


Free Float
Market Cap
$49.56 million
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Philip A. Serlin CPA (Age 64)
    M.B.A., CPA, MBA, Chief Executive Officer
    Comp: $598k
  • Ms. Mali Zeevi CPA (Age 48)
    CPA, Chief Financial Officer
    Comp: $374k
  • Dr. Ella Sorani Ph.D. (Age 56)
    Chief Development Officer
    Comp: $452k
  • Ms. Holly W. May M.B.A. (Age 62)
    President of BioLineRx USA
    Comp: $710k
  • Mr. John Lacey
    Head of Corporate Communications & Investor Relations
  • Ms. Tsipi Keren-Lehrer B.Sc.
    L.L.B., Head of BD & Strategic Advisor
  • Mr. Raziel Fried
    Treasurer & Budgetary Control Director

BLRX Stock Analysis - Frequently Asked Questions

Should I buy or sell BioLineRx stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLineRx in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BLRX shares.
View BLRX analyst ratings
or view top-rated stocks.

What is BioLineRx's stock price target for 2024?

1 Wall Street analysts have issued 12 month price targets for BioLineRx's shares. Their BLRX share price targets range from $21.00 to $21.00. On average, they predict the company's stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 3,287.1% from the stock's current price.
View analysts price targets for BLRX
or view top-rated stocks among Wall Street analysts.

How have BLRX shares performed in 2024?

BioLineRx's stock was trading at $1.57 at the start of the year. Since then, BLRX stock has decreased by 60.5% and is now trading at $0.62.
View the best growth stocks for 2024 here

How were BioLineRx's earnings last quarter?

BioLineRx Ltd. (NASDAQ:BLRX) released its quarterly earnings results on Thursday, March, 28th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.07. The biotechnology company earned $4.80 million during the quarter, compared to analysts' expectations of $0.17 million. During the same quarter in the previous year, the business posted ($0.09) EPS.

What other stocks do shareholders of BioLineRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLineRx investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), KushCo (KSHB), Aeterna Zentaris (AEZS), CNBX Pharmaceuticals (CNBX), Pennsylvania Real Estate Investment Trust (PEI), Savara (SVRA), Bionano Genomics (BNGO) and

Who are BioLineRx's major shareholders?

BioLineRx's stock is owned by a variety of institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of BioLineRx?

Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BLRX) was last updated on 5/23/2024 by Staff

From Our Partners